Arcus Biosciences (RCUS) Interest Expenses (2017 - 2026)

Arcus Biosciences' Interest Expenses history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 50.0% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 33.33% increase from a year earlier, with the FY2025 full-year figure at $412.0 million, up 30.38% from the prior year.
• Interest Expenses slipped to $3.0 million in Q1 2026 per RCUS's latest filing, from $4.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $150.0 million in Q4 2022 and bottomed at $1.0 million in Q1 2024.
• The 5-year median for Interest Expenses is $3.0 million (2023), against an average of $13.2 million.
• Across the five-year window, Interest Expenses jumped 14900.0% in 2022 and sank 75.0% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $150.0 million in 2022, then tumbled by 98.0% to $3.0 million in 2023, then tumbled by 33.33% to $2.0 million in 2024, then soared by 100.0% to $4.0 million in 2025, then decreased by 25.0% to $3.0 million in 2026.
• Per Business Quant, the three latest RCUS Interest Expenses figures stand at $3.0 million (Q1 2026), $4.0 million (Q3 2025), and $1.0 million (Q2 2025).